Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC

Video

Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.

Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses results from the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer (CRC).

During a presentation at the 2019 Gastrointestinal Cancers Symposium, an overall survival benefit of approximately 2.5 months was found in patients with microsatellite-stable CRC.

This is exciting as it is the first finding, according to Wadlow, that shows a statistically significant improvement with a checkpoint inhibitor in the majority of this patient population.

See more from the 2019 Gastrointestinal Cancers Symposium.

Recent Videos
Related Content
MRD Monitoring Post-Transplant Predicts Survival in TP53-Mutant MDS/AML

MRD Monitoring Post-Transplant Predicts Survival in TP53-Mutant MDS/AML

Jordyn Sava
January 10th 2025
Article

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

ESOPEC & TRANSMET Trials Show Promise Across GI Cancers

ESOPEC & TRANSMET Trials Show Promise Across GI Cancers

Jordyn Sava
January 7th 2025
Article

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?

Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?

Jordyn Sava
December 30th 2024
Article

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.

Read More

Bridging the Gap: Telehealth Expands Access to Essential Palliative Care

Bridging the Gap: Telehealth Expands Access to Essential Palliative Care

Sabrina Serani
December 26th 2024
Article

Joseph Greer, PhD, discussed a study evaluating in-person vs telehealth modalities of early integrated palliative care for patients with advanced lung cancer.

Read More